according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.18
 28.09.2024
 1609214-00020
 Date of first issue: 01.05.2017

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Timolol Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- :

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Piercetown

A86 HD21 Dunboyne, Ireland

Telephone : 908-740-4000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

### 1.4 Emergency telephone number

1-908-423-6000

#### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

# Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated exposure, Category 1, Cardio-vascular system, Lungs

H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements

### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word : Danger

Hazard statements : H372

Causes damage to organs (Cardio-vascular system, Lungs) through prolonged or repeated expo-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.18
 28.09.2024
 1609214-00020
 Date of first issue: 01.05.2017

sure.

Precautionary statements : Prevention:

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this prod-

uct.

Response:

P314 Get medical advice/ attention if you feel unwell.

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

# **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

Components

Chemical name	CAS-No. EC-No.	Classification	Concentration (% w/w)
	Index-No.		(/ 5 111 11)
	Registration number		
(S)-3-[3-(tert-butylamino)-2-	26921-17-5	Acute Tox. 4; H302	>= 0.1 - < 1
hydroxypropoxy]-4-morpholino-	248-111-5	Repr. 2; H361d	
1,2,5-thiadiazole monomaleate		STOT RE 1; H372	
		(Lungs, Cardio-	
		vascular system)	

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.18
 28.09.2024
 1609214-00020
 Date of first issue: 01.05.2017

when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Causes damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

### **SECTION 5: Firefighting measures**

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Phosphorus compounds

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.18
 28.09.2024
 1609214-00020
 Date of first issue: 01.05.2017

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

# **SECTION 7: Handling and storage**

## 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.18
 28.09.2024
 1609214-00020
 Date of first issue: 01.05.2017

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

# 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazolemonomaleate	26921-17-5	TWA	10 μg/m3 (OEB 3)	Internal
	Further information: Eye, Skin			
		Wipe limit	100 μg/100 cm <sup>2</sup>	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.18
 28.09.2024
 1609214-00020
 Date of first issue: 01.05.2017

Substance name	End Use	Exposure routes	Potential health effects	Value
Disodium hy- drogenorthophos- phate	Workers	Inhalation	Long-term systemic effects	4.07 mg/m3
	Consumers	Inhalation	Long-term systemic effects	3.04 mg/m3

#### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Disodium hydrogenorthophos-	Fresh water	0.05 mg/l
phate		_
	Marine water	0.005 mg/l
	Intermittent use/release	0.5 mg/l
	Sewage treatment plant	50 mg/l

### 8.2 Exposure controls

### **Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.18
 28.09.2024
 1609214-00020
 Date of first issue: 01.05.2017

# **SECTION 9: Physical and chemical properties**

9.1 Information on basic physical and chemical properties

Physical state : Aqueous solution

Colour : Colorless to pale yellow

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

No data available

Vapour pressure : No data available

Density : No data available

Relative vapour density : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.18 28.09.2024 1609214-00020 Date of first issue: 01.05.2017

Particle characteristics

Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : Not applicable

# **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

# **SECTION 11: Toxicological information**

# 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation exposure Skin contact

Ingestion Eye contact

# **Acute toxicity**

Not classified based on available information.

#### **Components:**

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Acute oral toxicity : LD50 (Rat): 1,000 mg/kg

LD50 (Mouse): 1,140 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.18 28.09.2024 1609214-00020 Date of first issue: 01.05.2017

Acute toxicity (other routes of: LD50 (Mouse): 300 mg/kg

administration)

Application Route: Intraperitoneal

LD50 (Mouse): 800 mg/kg

Application Route: Subcutaneous

#### Skin corrosion/irritation

Not classified based on available information.

### Components:

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species Rabbit Method **Draize Test** Result No skin irritation

# Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

**Species** Rabbit

Result Mild eye irritation

**Species** Dog

Result No eye irritation

### Respiratory or skin sensitisation

### Skin sensitisation

Not classified based on available information.

### Respiratory sensitisation

Not classified based on available information.

# Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Test Type: Bacterial reverse mutation assay (AMES) Genotoxicity in vitro

Method: OECD Test Guideline 471

Result: negative

Genotoxicity in vivo Test Type: In vivo micronucleus test

Species: Mouse

Method: OECD Test Guideline 474

Result: negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Timolol Formulation**

Version **Revision Date:** SDS Number: Date of last issue: 06.04.2024 28.09.2024 1609214-00020 Date of first issue: 01.05.2017 2.18

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Rat Species Application Route Oral Exposure time 2 Years

LOAEL 300 mg/kg body weight

Result negative **Target Organs** Adrenal gland

Remarks The significance of these findings for humans is not certain.

**Species** Mouse, female

Application Route Oral Exposure time 18 Months

LOAEL 500 mg/kg body weight

Result negative

**Target Organs** Lungs, Mammary gland, Uterus (including cervix)

The significance of these findings for humans is not certain. Remarks

Carcinogenicity - Assess-

ment

cinogen

# Reproductive toxicity

Not classified based on available information.

### **Components:**

# (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Effects on fertility Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL Mating/Fertility: 150 mg/kg body weight Early Embryonic Development: NOAEL F1: 150 mg/kg body

Weight of evidence does not support classification as a car-

weight

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: LOAEL F1: 50 mg/kg body weight Result: Some evidence of adverse effects on development,

based on animal experiments.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

# STOT - single exposure

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.18 28.09.2024 1609214-00020 Date of first issue: 01.05.2017

#### STOT - repeated exposure

Causes damage to organs (Cardio-vascular system, Lungs) through prolonged or repeated exposure.

**Product:** 

Target Organs : Cardio-vascular system, Lungs

Causes damage to organs through prolonged or repeated Assessment

exposure.

### Components:

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

**Target Organs** Lungs, Cardio-vascular system

Assessment Causes damage to organs through prolonged or repeated

exposure.

### Repeated dose toxicity

#### Components:

### (S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species Rat NOAEL 25 mg/kg Application Route Oral Exposure time 67 Weeks

**Species** Dog **NOAEL** 10 mg/kg Application Route Oral Exposure time : 54 Weeks **Target Organs** : Kidney

#### **Aspiration toxicity**

Not classified based on available information.

### 11.2 Information on other hazards

#### **Endocrine disrupting properties**

#### **Product:**

Assessment The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **Experience with human exposure**

### **Product:**

General Information May cause

> Stomach/intestinal disorders Respiratory disorders

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Timolol Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.18 28.09.2024 1609214-00020 Date of first issue: 01.05.2017

Symptoms: Irregular cardiac activity, central nervous system

effects

Eye contact : Symptoms: burning or stinging of the eye

**Components:** 

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Eye contact : Symptoms: burning or stinging of the eye, dryness of the

eyes, Headache, Nausea, Dizziness, dry mouth, changes in

libido, hair loss, Allergic reactions

Ingestion : Symptoms: Headache, Fatigue, Respiratory disorders, Gas-

trointestinal discomfort, Allergic reactions, Rash, hair loss,

altered mental status, Dizziness, changes in libido

### **SECTION 12: Ecological information**

#### 12.1 Toxicity

#### **Components:**

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 411 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 161 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to microorganisms : EC50 : > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition

EC50 (Photobacterium phosphoreum): > 1,800 mg/l

#### 12.2 Persistence and degradability

### **Components:**

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 0 % Exposure time: 30 d

Stability in water : Hydrolysis: 0 %(61 d)

Method: FDA 3.09

# 12.3 Bioaccumulative potential

#### **Components:**

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Partition coefficient: n-

octanol/water

: log Pow: 1.48

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.18
 28.09.2024
 1609214-00020
 Date of first issue: 01.05.2017

### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

### **Product:**

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

### 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

**ADN** : Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Timolol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.18
 28.09.2024
 1609214-00020
 Date of first issue: 01.05.2017

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

# 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

# **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is appli-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Timolol Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.18
 28.09.2024
 1609214-00020
 Date of first issue: 01.05.2017

cable to the placing on the market or

not.

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone

layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

#### Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

# 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

# **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

**Full text of H-Statements** 

H302 : Harmful if swallowed.

H361d : Suspected of damaging the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Test-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Timolol Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 1609214-00020 Date of first issue: 01.05.2017

ing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance: PICCS - Philippines Inventory of Chemicals and Chemical Substances: (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

STOT RE 1 H372

Based on product data or assessment

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN

Sheet